Allogene Therapeutics (ALLO) SEC Filings: History & Chart

Allogene Therapeutics, Inc.(ALLO)

Biotechnology · South San Francisco, CA

$1.46-0.04 (-2.67%)

Delayed quote: Oct 6, 2026, 12:00 PM EDT

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

151 employees

www.allogene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Zachary Roberts

View full financials

Form	Filing Date	Accepted	Document
SC 13D/A	Sep 30, 2026	Sep 30, 2026	View filing
8-K	Sep 2, 2026	Sep 2, 2026	View filing
4	Aug 25, 2026	Aug 25, 2026	View filing
EFFECT	Aug 20, 2026	Aug 21, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
S-3	Aug 12, 2026	Aug 12, 2026	View filing
10-Q	Aug 12, 2026	Aug 12, 2026	View filing
8-K	Aug 12, 2026	Aug 12, 2026	View filing
SC 13G/A	Aug 7, 2026	Aug 7, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
424B5	Jun 22, 2026	Jun 22, 2026	View filing
DEFA14A	May 28, 2026	May 28, 2026	View filing
8-K	May 28, 2026	May 28, 2026	View filing
DEFA14A	May 21, 2026	May 20, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 13, 2026	May 13, 2026	View filing
SC 13G/A	May 13, 2026	May 13, 2026	View filing
10-Q	May 13, 2026	May 13, 2026	View filing
8-K	May 13, 2026	May 13, 2026	View filing
ARS	Apr 30, 2026	Apr 30, 2026	View filing

SEC Filings

Recent Filings